UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 285

Sortiert nach

Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors

Journal of the National Comprehensive Cancer Network, 2024-02, Vol.22 (1)

2024

Link zum Volltext

Verfügbarkeit prüfen

Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia

British journal of haematology, 2023-09, Vol.202 (6), p.1084-1086

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply to “Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!”

Cancer, 2023-07, Vol.129 (14), p.2268-2268

2023

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience

BMC cancer, 2023-09, Vol.23 (1), p.1-817, Article 817

2023

Link zum Volltext

Verfügbarkeit prüfen

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades

Journal of hematology and oncology, 2023-03, Vol.16 (1), p.22-22, Article 22

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment discontinuation in chronic myeloid leukemia: When, how, and why?

American journal of hematology, 2023-11, Vol.98 (11), p.1670-1672

2023

Link zum Volltext

Verfügbarkeit prüfen

EXABS-133-ALL Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22 Suppl 2, p.S39-S41

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019

Cancer, 2023-12, Vol.129 (23), p.3805-3814

2023

Link zum Volltext

Verfügbarkeit prüfen

The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia

American journal of hematology, 2024-06, Vol.99 (6), p.1175-1176

2024

Link zum Volltext

Verfügbarkeit prüfen

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?

Hematology, 2022-12, Vol.2022 (1), p.213

2022

Link zum Volltext

Verfügbarkeit prüfen

Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia

Expert opinion on pharmacotherapy, 2022-05, Vol.23 (7), p.751-758

2022

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children’s Leukemia Group-AML 2015 Study

Translational pediatrics, 2024-02, Vol.13 (2), p.376-379

2024

Link zum Volltext

Verfügbarkeit prüfen

Ponatinib‐review of historical development, current status, and future research

American journal of hematology, 2024-08, Vol.99 (8), p.1576-1585

2024

Link zum Volltext

Verfügbarkeit prüfen

Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

American journal of hematology, 2022-07, Vol.97 (7), p.856-864

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab

Journal of Immunotherapy and Precision Oncology, 2021-05, Vol.4 (2), p.67-71

2021

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era

American journal of hematology, 2023-10, Vol.98 (10), p.1619-1626

2023

Link zum Volltext

Verfügbarkeit prüfen

Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase

Cancer, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

Leukemia, 2024-05, Vol.38 (5), p.947-950

2024

Link zum Volltext

Verfügbarkeit prüfen

SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Clinical lymphoma, myeloma and leukemia, 2024-05, Vol.24 (5), p.271-276

2024

Link zum Volltext

Verfügbarkeit prüfen

Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia

International journal of hematology, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab

European journal of cancer (1990), 2018-03, Vol.91, p.171-173

2018

Link zum Volltext

Verfügbarkeit prüfen

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

American journal of hematology, 2023-03, Vol.98 (3), p.493-501

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Blood, 2024-02, Vol.143 (5), p.417

2024

Link zum Volltext

Verfügbarkeit prüfen

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring

Leukemia & lymphoma, 2023-02, Vol.64 (3), p.746-749

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 285

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(256)
Mit Volltextzugriff
(253)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors

Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia

Reply to “Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!”

PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades

Treatment discontinuation in chronic myeloid leukemia: When, how, and why?

EXABS-133-ALL Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019

The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?

Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia

The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children’s Leukemia Group-AML 2015 Study

Ponatinib‐review of historical development, current status, and future research

Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era

Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia

Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring

Suchergebnisse filtern